Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

NanoInterventions unveils rapid testing system for coronary stents

NanoInterventions : 19 June, 2008  (New Product)
NanoInterventions has introduced the ‘Mouse Stent Model’ for rapid screening of new coronary stent therapeutics.
The model, complete with a mini-stent of small size and its ability to replicate the human diseased vessel, represents a new starting point in the development of next-generation drug-eluting coronary stents. The company, NanoInterventions,has emerged from the strategic global partnership of Minnesota-based The Integra Group of Brooklyn Park and Nanocopoeia of St Paul, along with Stentome, with operations in Palo Alto, California, USA, Galway, Ireland and Oxford, UK, and the University of Western Ontario, in London, Ontario, Canada.

Minnesota is already home to two of the three largest Stent manufacturers and one of the largest clusters of medical device companies in the world. With its local headquarters and base of operations, combined with its global network of partners, NanoInterventions is ideally positioned to speed the development of these life saving devices. The new starting point for testing new stent-delivered therapies brings the customer many novel benefits, including: establishing efficacy much earlier in the process, speeding development-the experimental model requires 28 day cycle versus a 180 day average cycle-and exploring molecular mechanisms of action in the setting of a stented, diseased vessel.

NanoInterventions' managing partner, Robert A Hoerr, MD, PhD, who is Nanocopoeia's chief executive officer, stated, 'Our position within the heart of Minnesota's world-class medical device community enabled us to build strategic relationships with the talent and technology needed to launch this new development pathway for therapeutic coronary stents. We fully expect that our position at this new starting point for Stent development will create a family of new, high-value cardiovascular devices.'

The Mouse Stent Model is a fast, predictive model of how a new therapeutic will affect the diseased human artery when implanted as part of a drug-eluting stent. The high-throughput system provides the ideal method to screen therapeutic leads advancing from pharmaceutical and biotech companies as well as university laboratories. Many of these have not had ready access to the specialised tools or expertise needed to evaluate the potential value of their leads for interventional cardiology applications.

NanoInterventions can assist companies assess the potential value of their therapeutic discoveries for device-delivered treatments and chart a path for further development, thereby enhancing the value of their intellectual property and creating a justification for the later, more costly development programme required to advance a cardiovascular combination device toward regulatory approval - and potentially licensing rights to or selling the newly enhanced asset.

The wide-ranging expertise within the Minnesota-based partnership can guide combination drug/devices from concept through clinical trials and regulatory approval. The Integra Group anchors the development operations with its extensive experience in early stage cardiovascular research and managing complex development programs, beginning with non-human testing and extending to approval-pathway clinical trials.

Nanocopoeia, an innovator in producing nanoengineered drug coatings for medical devices, incorporates the candidate drugs or biologics into the mini-stent coating. Coating the mini-stent is a special challenge for which its ElectroNanospray process is suited. Stentome, a partnership of cardiovascular scientists and bioengineers, led design of the mini-stent developed its current microfabrication process in Galway; and devised the complex surgical procedure for implanting the stent. Its scientific team contributes cutting edge expertise in cardiovascular medicine and molecular biology derived from ongoing, active research programs at Oxford and Stanford Universities.

The University of Western Ontario, one of Canada's leading research-centred universities, contributes its robust drug-eluting polymer platform, which can be flexibly configured to deliver a broad range of drugs and biologics.

'We are thrilled to bring our operational and regulatory development expertise to this exciting venture and helping to establish it as a key new tool for the medical device, pharma/biotech and academic communities,' commented Chris Pulling, chief executive officer of The Integra Group. 'NanoInterventions' synergistic technology and core competencies of research and engineering will save time and resources to bring more affordable, life-saving therapies to our health care system.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo